Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection

Inclusion Criteria: * Healthy male aged 18-40. * The body mass index is in the range of 19-26 kg/m2 (including thecritical value). The weight is 50 kg-80kg. * The subjects have no family planning within 3 months and could select contraceptive method * The subjects who have signed the informed consent and are able to complete the experiment according to the trial protocol. * Echocardiography showed left ventricular ejection fraction (LVEF) \> 50% ,which two weeks before administration of experimental drug. Exclusion Criteria: * The subjects with a history of malignant tumor. * The subjects who has received any live vaccine within 6 months prior to signing the informed consent. * The subjects who has upper respiratory tract infection or other acute infections within the previous 2 weeks of screening. * The subjects who had undergone surgery within 2 months prior to signing the informed consent. * Anti-drug antibody (ADA) detection positive. * Previous treatment with any antibody targeting the HER2 receptor or Those who have used monoclonal antibodies within 6 months prior to signing the informed consent.